NCT05035589View on ClinicalTrials.gov

The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

October 20, 2021

Study Completion Date

November 20, 2021

Conditions
COVID-19 PneumoniaARDS
Interventions
DRUG

Tocilizumab

Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg

Trial Locations (1)

MSD2090

Mater Dei Hospital, Msida

All Listed Sponsors
collaborator

Mater Dei Hospital, Malta

OTHER

lead

Sciberras, Stephen M.D.

INDIV

NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter